UNSPSC 51162647: Pentoxyverine citrate

This classification denotes an antitussive agent with the molecular structure C20H31NO3.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 4SH0MFJ5HJ chemically known as cyclopentanecarboxylic acid, 1-phenyl-, 2-(2-(diethylamino)ethoxy)ethyl ester, citrate (1:1), but more commonly known as pentoxyverine citrate, which bears US NIH Compound Identifier 90010. European Medicines Agency schedules Pentoxyverine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03695MIG.

UNSPSC 51162647 Pentoxyverine citrate is a Commodity code that, based on recent state and local solicitations, encompasses pharmaceutical products procured through both direct purchase and cooperative purchasing mechanisms. The recent activity under this code reflects state and local procurement of naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers and community health facilities. Issuing bodies include county health departments and multistate cooperative purchasing alliances administering pharmaceuticals across participating state and local government facilities, with the Minnesota Department of Administration's Office of State Procurement coordinating cooperative purchasing on behalf of multiple states and localities.

The geographic spread of recent activity centers on Florida and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) extending coverage to Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County, Florida's competitive bid for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB 60459723LAS, due July 26, 2023), requiring quarterly deliveries to the Seminole County Community Health Building with a two-year initial term and one-year renewal option; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026) through authorized wholesalers AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC, with contract awards effective July 1, 2026 and a two-year term. Both solicitations require vendors to meet cGMP and FDA compliance standards, maintain specified insurance coverage, and submit pricing through electronic procurement portals. The MMCAP opportunity weights price competitiveness at 75 percent of evaluation criteria and imposes a 3 percent administrative fee on all contract purchases.